Literature DB >> 11375134

Cognitive screening and neuropsychological assessment in early Alzheimer's disease.

D P Salmon1, K L Lange.   

Abstract

Cognitive screening and detailed neuropsychological assessment provide a reliable means of detecting dementia in its earliest stages, tracking the progression of cognitive decline over time, and aiding in the differential diagnosis of various dementing disorders. In addition, recent studies have shown that mild cognitive changes, and particularly declines in memory function, are evident in the "preclinical" phase of Alzheimer's disease and may help to identify elderly individuals who are likely to develop dementia in the near future. Until effective and easily obtainable biological markers for detecting the onset and progression of Alzheimer's disease are developed, neuropsychological assessment will continue to have an important role in the dementia evaluation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375134     DOI: 10.1016/s0749-0690(05)70067-7

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  6 in total

1.  An approach for estimating item sensitivity to within-person change over time: An illustration using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog).

Authors:  N Maritza Dowling; Daniel M Bolt; Sien Deng
Journal:  Psychol Assess       Date:  2016-01-25

2.  High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration.

Authors:  Jie Liu; Vladimir Kepe; Alenka Zabjek; Andrej Petric; Henry C Padgett; Nagichettiar Satyamurthy; Jorge R Barrio
Journal:  Mol Imaging Biol       Date:  2007 Jan-Feb       Impact factor: 3.488

3.  Impacts of AD-Related ABCA7 and CLU Variants on Default Mode Network Connectivity in Healthy Middle-Age Adults.

Authors:  Xin Yuan Zhang; Yun Fei Wang; Li Juan Zheng; Han Zhang; Li Lin; Guang Ming Lu; Long Jiang Zhang
Journal:  Front Mol Neurosci       Date:  2020-07-31       Impact factor: 5.639

4.  Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease.

Authors:  Chong Wang; Jin-Tai Yu; Hui-Fu Wang; Teng Jiang; Chen-Chen Tan; Xiang-Fei Meng; Holly D Soares; Lan Tan
Journal:  PLoS One       Date:  2014-02-18       Impact factor: 3.240

5.  MS4A6A genotypes are associated with the atrophy rates of Alzheimer's disease related brain structures.

Authors:  Jing Ma; Wei Zhang; Lin Tan; Hui-Fu Wang; Yu Wan; Fu-Rong Sun; Chen-Chen Tan; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2016-09-13

6.  Impact of Common Variations in PLD3 on Neuroimaging Phenotypes in Non-demented Elders.

Authors:  Chong Wang; Hui-Fu Wang; Meng-Shan Tan; Ying Liu; Teng Jiang; Dao-Qiang Zhang; Lan Tan; Jin-Tai Yu
Journal:  Mol Neurobiol       Date:  2015-08-01       Impact factor: 5.590

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.